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The objective of this study was to investigate the effect of tiotropium compared with salme-
terol on exacerbations in patients with moderate (Global Initiative for Chronic Obstructive
Lung Disease [GOLD] stage II) chronic obstructive pulmonary disease (COPD) and those naı¨ve
to maintenance respiratory therapy in the 1-year Prevention Of Exacerbations with Tiotropium
in COPD (POET-COPD) trial (NCT00563381). Time to first exacerbation (primary endpoint)
and rates of exacerbations were analyzed using exploratory Cox and Poisson regression (adjust-
ing for time on treatment). Of 7376 randomized patients, 3614 were GOLD stage II (tiotropium
n Z 1781; salmeterol n Z 1833) and 1343 were maintenance therapy naı¨ve (tiotropium
n Z 672; salmeterol n Z 671). Tiotropium significantly increased time to first exacerbation
vs. salmeterol in GOLD stage II patients (hazard ratio [HR], 0.88; 95% confidence
interval [CI]: 0.79e0.99; p Z 0.028) and maintenance therapy naı¨ve patients (HR, 0.79; 95%
CI, 0.65e0.97; pZ 0.028). Annual exacerbation rates were also significantly lower with tiotro-
pium in the maintenance naı¨ve subgroup compared with salmeterol (rate ratio [RR], 0.77; 95%
CI, 0.63e0.94; p Z 0.012). In the GOLD stage II subgroup, the rate of hospitalized exacerba-
tions per year was significantly lower with tiotropium than with salmeterol (RR, 0.70; 95%
CI, 0.57e0.85; p < 0.001); tiotropium also significantly prolonged time to first hospitalized21 586 6451; fax: þ49 6421 286 8987.
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Global Initiative for Chronic Obstr
Obstructive Pulmonary Disease.exacerbation versus salmeterol in this subgroup (HR, 0.66; 95% CI, 0.48e0.91; p Z 0.012). In
conclusion, results from this prespecified subgroup analysis support the selection of tiotropium
as first-choice maintenance therapy for patients with GOLD stage II COPD.
ª 2012 Elsevier Ltd. All rights reserved.Introduction
Exacerbations are a key clinical characteristic of chronic
obstructive pulmonary disease (COPD) and are strongly
associated with disease progression, worsening lung func-
tion, dyspnea, deteriorating health status/physical activity,
and an increased risk of mortality.1e5 Indeed, exacerba-
tions have become a recognized disease-defining feature of
COPD in the recent update of the Global Initiative for
Chronic Obstructive Lung Disease (GOLD) committee.6
Long-term, controlled trials have examined the effect on
COPD exacerbations of early bronchodilator maintenance
therapy.1,7 Previous subgroup analyses of the 4-year Under-
standing Potential Long-term Impacts on Function with Tio-
tropium (UPLIFT) trial demonstrated that treatment with
tiotropium increased the time to first exacerbation and
exacerbations resulting in hospital admission in COPD
patients with GOLD stage II disease, comparedwith control.7
A reduction in the rate of exacerbations was also noted for
patients who were naı¨ve to maintenance treatment.8
Results have now become available from the Prevention
Of Exacerbations with Tiotropium in COPD (POET-COPD)
study,9 a 1-year, randomized, double-blind, double-
dummy, parallel-group trial of 7376 patients with moderate
to very severe COPD that compared the effect of treatment
with the long-acting anticholinergic tiotropium (18 mg via
HandiHaler once daily) and the long-acting b2-agonist
(LABA) salmeterol (50 mg via hydrofluoroalkane-pressurized
metered-dose inhaler [HFA-pMDI] twice daily) on thee II and maintenance naı¨ve pat
uctive Lung Disease; POET-COPincidence of exacerbations. Compared with salmeterol,
tiotropium significantly increased time to first exacerbation
(p < 0.001) and time to first severe exacerbation
(p < 0.001), and reduced annual rates of moderate or
severe exacerbations (pZ 0.002) and severe exacerbations
(p < 0.001) in the overall study population.
Toexplore the relativeeffects of therapywith tiotropiumor
salmeterol on exacerbation outcomes further, we conducted
prespecified subgroup analyses of the POET-COPD study
cohort in patients with moderate (GOLD stage II) disease, and
those who were maintenance naı¨ve. Results in these pop-
ulationswere considered alongside data from the subgroups of
patients inPOET-COPDwithGOLD stage III and IVdisease, and
those with prior maintenance therapy experience.Methods
Study design
POET-COPD was a randomized, double-blind, double-
dummy, 1-year trial. The study design has been described in
detail elsewhere.9,10 Briefly, patients were randomized to
tiotropium 18 mg once daily (via HandiHaler) plus placebo
twice daily (via HFA-pMDI), or salmeterol 50 mg twice daily
(via HFA-pMDI) plus placebo once daily (via HandiHaler).
All patients were instructed in the use of HandiHaler and
HFA-pMDI devices at visits 1 (screening) and 2 (randomiza-
tion). Patients who were receiving fixed-dose combinationsientsdprespecified subgroups of the POET-COPD trial. GOLD,
D, Prevention Of Exacerbations with Tiotropium in Chronic
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instructed to switch to ICS monotherapy at the start of
randomized treatment. Patients were allowed to continue
their usual COPD medication, except for anticholinergics or
LABAs, during the double-blind treatment phase. Patients
were considered “maintenance naı¨ve” if they were exclu-
sively using short-acting b2-agonists, or none of the
following maintenance medications at baseline: ICS,
systemic corticosteroids, xanthines, anticholinergics (short-
or long-acting), and LABAs.
The primary endpoint of the trial was time to first
moderate or severe exacerbation. Secondary endpoints
included the annual rate of moderate or severe exacerba-
tions, serious adverse events, and mortality.
Patients
Criteria for participation included a diagnosis of COPD;
age 40 years; a smoking history 10 pack-years;
postbronchodilator forced expiratory volume in 1 s
[FEV1] 70% predicted and FEV1 70% of forced vitalTable 1 Baseline characteristics in GOLD stage II, GOLD stage I
patients.
Analysis GOLD stage IIa GOLD stage III an
Tiotropium
(n Z 1781)
Salmeterol
(n Z 1833)
Tiotropium
(n Z 1926)
Salm
(n Z
Male, % 69.8 68.8 78.7 80.9
Age, years 63.3  9.2 63.2  9.4 62.6  8.8 62.5
Smoking status
Current smoker, % 47.1 47.8 48.8 48.8
Smoking history,
pack-years
37.7  19.8 37.0  18.8 39.7  20.1 38.6
COPD duration,
years
7.5  6.6 7.4  6.6 8.5  6.8 8.4
BMI, kg/m2 27.2  5.1 27.2  5.0 26.1  5.1 26.0
FEV1, L 1.72  0.40 1.70  0.39 1.12  0.31 1.13
FEV1, % predicted 60.7  6.6 60.2  6.7 38.5  8.0 38.5
FEV1/FVC, % 57.5  8.8 57.5  8.9 47.9  10.5 47.3
GOLD severity stage, %b
I e e e e
II e e e e
III e e e e
IV
Pulmonary
medicine use, %
89.4 88.6 90.5 91.2
SAAC 27.5 26.7 31.0 32.5
LAAC 29.0 29.4 31.9 31.1
SABA 50.1 49.4 54.7 57.4
LABA 51.0 50.9 52.0 52.2
ICS 51.1 49.0 55.9 57.6
Xanthines 20.5 17.7 25.2 24.6
BMI, body mass index; COPD, chronic obstructive pulmonary disease;
GOLD, Global Initiative for Chronic Obstructive Lung Disease; ICS, inha
acting b2-agonist; SAAC, short-acting anticholinergic; SABA, short-act
a Twenty-three GOLD stage I patients were included in the GOLD st
b Percentages do not total 100% due to rounding. Data are mean capacity; 1 exacerbation in the previous year
requiring treatment with systemic corticosteroids or
antibiotics (moderate exacerbation) or hospitalization
(severe exacerbation).
Assessments
Patient baseline characteristics were recorded, including
demographics, lung function, and pulmonary medication
use. Data on exacerbations and medication use/hospitali-
zation for exacerbations were collected using a daily diary
card and a questionnaire administered during clinic visits
and telephone contacts. An exacerbation was defined as an
increase or new onset of more than one symptom (cough,
sputum, wheezing, dyspnea, chest tightness), with at least
one symptom lasting at least 3 days and requiring treat-
ment with systemic corticosteroids and/or antibiotics
(moderate exacerbation) or hospitalization (severe
exacerbation).
Serious adverse events, including fatal events, were
recorded at each clinic visit.II and IV, maintenance naı¨ve, and prior maintenance therapy
d IV Maintenance therapy
naı¨ve
Prior maintenance
therapy
eterol
1836)
Tiotropium
(n Z 672)
Salmeterol
(n Z 671)
Tiotropium
(n Z 3035)
Salmeterol
(n Z 2998)
73.5 70.8 74.6 75.8
 8.6 60.8  9.4 61.1  9.5 63.4  8.8 63.2  8.9
61.6 61.0 44.9 45.5
 19.6 35.2  18.4 34.0  18.9 39.5  20.2 38.7  19.2
 6.5 8.0  6.7 7.9  6.8 8.0  6.7 7.9  6.5
 5.1 26.4  5.0 27.2  5.3 26.7  5.1 26.5  5.1
 0.30 1.46  0.51 1.48  0.50 1.40  0.45 1.40  0.44
 8.1 49.7  14.4 50.5  13.9 49.1  13.1 49.1  13.0
 11.0 55.3  11.4 55.7  11.0 51.9  10.6 51.6  11.1
0.7 0.9 0.1 0.3
48.2 54.1 47.7 48.5
41.2 37.1 43.5 43.2
9.8 7.9 8.7 7.9
44.6 44.7 100 100
e e 35.8 36.2
e e 37.3 37.0
44.3 44.0 54.3 55.5
e e 62.9 63.1
e e 65.4 65.2
e e 28.0 25.9
FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity;
led corticosteroid; LAAC, long-acting anticholinergic; LABA, long-
ing b2-agonist.
age II group altogether.
standard deviation unless specified otherwise.
Figure 2 KaplaneMeier estimates of probability of first COPD exacerbation for tiotropium and salmeterol in: A) GOLD stage II;
B) GOLD stage III and IV; C) maintenance naı¨ve; and D) prior maintenance therapy subgroups. COPD, chronic obstructive pulmonary
disease; GOLD, Global Initiative for Chronic Obstructive Lung Disease.
Figure 3 Subgroup analysis of the primary endpoint “time to first COPD exacerbation” for COPD severity stage (GOLD) and for
patients who were maintenance therapy naı¨ve or receiving prior maintenance therapy. Hazard ratios were calculated with the use
of Cox regression adjusting for treatment. Horizontal lines represent 95% confidence intervals. Subgroup by treatment interaction p
value based on Cox regression adjusted for treatment, subgroup, and subgroup-by-treatment interaction: COPD severity stage
(GOLD II/III and IV) p Z 0.371; maintenance naı¨ve at baseline (yes/no) p Z 0.479. COPD, chronic obstructive pulmonary disease;
GOLD, Global Initiative for Chronic Obstructive Lung Disease; n, number of patients with at least one COPD exacerbation; N,
number of randomized and treated patients.
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All analyses (GOLD stage II, III and IV, maintenance naı¨ve,
and prior maintenance therapy subgroups) were pre-
specified. In line with the primary analysis of the trial,9
a Cox proportional hazards regression model was used for
time-to-event (exacerbation and mortality) analyses.
Hazard ratios (HR) and p-values were based on subgroup-
restricted Cox regression with treatment as covariate.
Poisson regression, correcting for overdispersion and
adjusting for treatment exposure and with terms for
subgroup and treatment-by-subgroup interaction, was used
for number-of-event analyses.Figure 4 A) Exacerbation rates and B) Hospitalized exacer-
bations rates per patient-year for GOLD stage II, GOLD stage III
and IV, maintenance naı¨ve, and prior maintenance therapy
patients. Subgroup by treatment interaction p-value and rate
ratios were calculated as described in the Methods: A) Exac-
erbations: COPD severity stage (GOLD II/GOLD III and IV),
pZ 0.617; maintenance naı¨ve at baseline (yes/no) pZ 0.132;
B) Hospitalized exacerbations: COPD severity stage (GOLD II/
GOLD III and IV), p Z 0.750; maintenance naı¨ve at baseline
(yes/no), p Z 0.787. CI, confidence interval; COPD, chronic
obstructive pulmonary disease; GOLD, Global Initiative for
Chronic Obstructive Lung Disease.Results
Baseline characteristics
A total of 7376 patients were randomized and treated in the
POET-COPD trial, of whom 3614 were GOLD stage II COPD
(tiotropium n Z 1781; salmeterol n Z 1833); 1343 were
maintenance naı¨ve (tiotropium n Z 672; salmeterol
n Z 671), whereas 3762 were GOLD stage III and IV (tio-
tropium n Z 1926; salmeterol n Z 1836); and 6033 had
received prior maintenance therapy at time of randomiza-
tion (tiotropium n Z 3035; salmeterol n Z 2998). Patient
disposition is detailed in Fig. 1. Baseline characteristics
were well balanced between patients receiving tiotropium
and salmeterol within each of the four subgroups (Table 1).
Mean age was similar across the GOLD stage and mainte-
nance therapy subgroups (ranging from 60.8 to 63.4 years),
and a similar proportion of patients at each GOLD stage
were within the maintenance therapy naı¨ve and prior
maintenance therapy subgroups (GOLD stage II, 51.2%e
48.1%; GOLD stage III, 39.2%e43.4%; GOLD stage IV, 8.9%e
8.3%). An approximately 16% higher proportion of current
smokers was noted in the maintenance naı¨ve subgroup
compared with patients receiving prior maintenance
therapy (61% vs. 45%), and fewer than 50% of patients in the
naı¨ve subgroup were receiving any pulmonary medication
(Table 1).
Exacerbation outcomes
Tiotropium significantly prolonged time to first exacerba-
tion in the GOLD stage II subgroup compared with salme-
terol (HR 0.88; 95% confidence interval [CI] 0.79e0.99;
pZ 0.028) (Fig. 2A). This was also true in the GOLD stage III
and IV subgroup (Fig. 2B) (HR 0.82; 95% CI 0.74e0.91;
p < 0.001). The subgroup-by-treatment interaction p-value
for the COPD severity stage category (GOLD stage II, GOLD
stage III and IV subgroups) was 0.37.
Tiotropium also significantly prolonged time to first
exacerbation in the maintenance naı¨ve subgroup compared
with salmeterol (HR 0.79; 95% CI 0.65e0.97; p Z 0.028)
(Fig. 2C). Time to first exacerbation results for the
subgroup of patients receiving prior maintenance treat-
ment were also significant in favor of tiotropium (HR 0.86;
95% CI 0.79e0.93; p < 0.001) (Fig. 2D). The subgroup-by-
treatment interaction p-value was 0.48 for themaintenance therapy category (maintenance naı¨ve and
receiving prior maintenance therapy subgroups).
Across all subgroups, an early separation of the tio-
tropium and salmeterol time curves was observed in the
KaplaneMeier plots (Fig. 2AeD), which was maintained up
to the 1-year time-point.
For the GOLD stage II subgroup, the rate of exacerba-
tions per year was numerically lower with tiotropium than
with salmeterol (0.55 vs. 0.60; rate ratio [RR] 0.91; 95% CI
0.81e1.01; p Z 0.072) (Figs. 3 and 4A). Annual exacerba-
tion rates were significantly lower with tiotropium
80 C. Vogelmeier et al.compared with salmeterol in the maintenance naı¨ve
subgroup (0.38 vs. 0.49; RR 0.77; 95% CI 0.63e0.94;
p Z 0.012); a similar behavior was also observed in the
maintenance therapy and GOLD stage III and IV subgroups
(Figs. 3 and 4A).
In the GOLD stage II subgroup, the rate of hospitalized
exacerbations per year was significantly lower with tio-
tropium than with salmeterol (0.05 vs. 0.07; RR 0.70; 95% CI
0.57e0.85; p < 0.001 [Fig. 4B]), while tiotropium also
significantly prolonged time to first hospitalized exacerba-
tion compared with salmeterol in this subgroup (HR 0.66;
95% CI 0.48e0.91; p Z 0.012 [Fig. 5A]). Both the annual
rate of hospitalized exacerbations and time to first hospi-
talized exacerbation for tiotropium compared with salme-
terol did not reach significance for the maintenance naı¨ve
subgroup (Figs. 4B and 5C); however, these results were
significant for the prior maintenance therapy subgroup
(rate of hospitalized exacerbations: 0.10 vs. 0.14; RR 0.73;Figure 5 KaplaneMeier estimates of probability of first hospit
A) GOLD stage II; B) GOLD stage III and IV; C) Maintenance naı¨ve; an
value based on subgroup-restricted Cox regression with treatmen
exacerbation based on Cox regression adjusted for treatment, sub
stage (GOLD II/GOLD III and IV), p Z 0.468; maintenance naı¨ve at
chronic obstructive pulmonary disease; GOLD, Global Initiative for95% CI 0.65e0.82; p < 0.001 [Fig. 4B]; time to first hospi-
talized exacerbation: HR 0.76; 95% CI 0.64e0.90; pZ 0.002
[Fig. 5D]).Safety
The total incidence of serious adverse events was 11.1% in
the tiotropium group and 11.7% in the salmeterol group in
the GOLD stage II subgroup (RR 0.93; 95% CI 0.77e1.13), and
11.2% and 12.7%, respectively, in the maintenance naı¨ve
subgroup (RR 0.87; 95% CI 0.63e1.18). The total incidence
of serious adverse events was higher with salmeterol both
in the GOLD stage III and IV subgroup (RR 0.81; 95% CI
0.70e0.94) and in the prior maintenance therapy subgroup
(RR 0.86; 95% CI 0.76e0.98) (Table 2).
The number of deaths was similar in the tiotropium
group compared with the salmeterol group in all subgroups.alized COPD exacerbation for tiotropium and salmeterol in:
d D) Prior maintenance therapy subgroups. Hazard ratios and p-
t as covariate. Interaction p-value for first hospitalized COPD
group, and subgroup-by-treatment interaction: COPD severity
baseline (yes/no), p Z 0.685. CI, confidence interval; COPD,
Chronic Obstructive Lung Disease.
Table 2 Serious adverse event incidence (1% in any group) by MedDRA SOC and preferred term: COPD disease stage and
maintenance therapy subgroups.
SOC/preferred term Incidence (%)
GOLD stage IIa GOLD stage III and IV Maintenance therapy
naı¨ve
Prior maintenance
therapy
Tiotropium
(n Z 1781)
Salmeterol
(n Z 1833)
Tiotropium
(n Z 1926)
Salmeterol
(n Z 1836)
Tiotropium
(n Z 672)
Salmeterol
(n Z 671)
Tiotropium
(n Z 3035)
Salmeterol
(n Z 2998)
Total serious adverse events 11.1 11.7 18.1 21.4 11.2 12.7 15.5 17.4
Cardiac disorders 2.5 1.3 2.8 3.3 1.8 1.5 2.8 2.5
Gastrointestinal disorders 0.7 0.5 1.0 1.3 0.4 1.2 1.0 0.8
Infections and infestations 1.7 2.3 3.4 3.6 1.3 2.2 2.9 3.1
Pneumonia 0.8 1.4 2.0 2.1 0.7 1.2 1.6 1.9
Neoplasms, benign malignant,
and unspecified
(including cysts and polyps)
1.3 1.3 1.5 1.0 1.3 0.7 1.4 1.3
Nervous system disorders 1.0 0.7 0.5 0.9 0.4 1.2 0.8 0.7
Respiratory, thoracic, and
mediastinal disorders
4.6 5.8 11.3 14.2 5.4 6.6 8.7 10.7
COPD 3.7 5.2 10.6 13.1 4.5 6.1 7.9 9.8
Vascular disorders 1.2 0.5 0.8 0.8 1.0 0.9 1.0 0.6
COPD, chronic obstructive pulmonary disease; GOLD, Global Initiative for Chronic Obstructive Lung Disease; MedDRA, Medical Dictionary
for Regulatory Activities (MedDRA v13.0 was used for reporting); SOC, system organ class.
a Twenty-three GOLD stage I patients were included in the GOLD stage II group.
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The results of these prespecified subgroup analyses of the
POET-COPD study showed that tiotropium significantly
prolonged time to first exacerbation compared with sal-
meterol in patients with GOLD stage II disease, and in those
who were previously naı¨ve to maintenance respiratory
therapy. The KaplaneMeier plots of time to first exacer-
bation illustrated an early onset of therapeutic benefit in
patients receiving tiotropium compared with salmeterol,
and the between-groups separation was maintained over
time. A significant lowering of the annual rate of exacer-
bations was also seen with tiotropium versus salmeterol in
the maintenance naı¨ve subgroup.
The present analyses expand on previous subgroup
evaluations of patients with moderate COPD from the
UPLIFT and Towards a Revolution in COPD Health (TORCH)
trials,11,12 in which a significant reduction in exacerbation
risk was observed during long-term treatment with tio-
tropium or salmeterol/fluticasone propionate, compared
with the control groups. Salmeterol appeared to be the best
comparator to tiotropium as it possesses the broadest
clinical database of all LABAs and has demonstrated
consistent efficacy on exacerbations of COPD.13
Our subgroup analyses of POET-COPD offer new infor-
mation, as they suggest that a diminished risk of exacer-
bations with tiotropium compared with salmeterol is also
achievable in patients with less severe disease and in
patients with no prior maintenance therapy. While treat-
ment guidelines recommend long-acting bronchodilators to
manage symptoms and reduce the risk of exacerbations in
patients with moderate to very severe COPD, they do not
specify whether a long-acting anticholinergic or LABA is the
preferred agent.6 It is noteworthy that patients in themaintenance naı¨ve subgroup were at least GOLD stage II on
enrollment into POET-COPD; according to current guide-
lines, these patients should have already been receiving
long-acting bronchodilator therapy.
In the GOLD stage II subgroup, the annual rate of
hospitalized exacerbations was significantly reduced while
tiotropium also significantly prolonged time to first severe
exacerbation. A trend toward a reduction in the rate of
exacerbations with tiotropium was shown in patients at
GOLD stage II, as well as a trend toward a reduction in the
rate of hospitalized exacerbations in maintenance naı¨ve
patients; however there was a lack of a significant effect in
both instances. This can be explained by a lack of statistical
power and the incidence of fewer exacerbations in these
subgroups of less severe disease.
Our serious adverse event results for tiotropium and sal-
meterol in the prespecified subgroups were consistent with
previously published safety profiles, and the GOLD stage II
and maintenance naı¨ve subgroups showed an incidence of
serious adverse events similar to that in the corresponding
groups of patients from the UPLIFT trial.8,11 There were no
significant differences in mortality between patients
receiving tiotropium and salmeterol in any subgroup during
the 1-year study period. This finding is consistent with
previous study outcomes and can be explained by the study
not being designed or powered to show a difference in
mortality between two effective long-acting
bronchodilators.9,11,12
The current subgroup analyses of the POET-COPD study
were preplanned, and the size of the patient population
allows inferences to be drawn about the real effects of
treatment on the exacerbation endpoints. However, as with
all subanalyses, the results may require confirmation
through additional research. The characterization of the
82 C. Vogelmeier et al.maintenance naı¨ve subgroup also had potential limitations,
such as the use of cross-sectional baseline data that did not
take into account potential prior prescriptions, the reliance
on patient-reported treatment history in many cases, and
the possibility of noncompliance in some patients from the
subgroup with prior maintenance therapy.
A key strength of the study was that the primary
endpoint of the study cohort was time to exacerbation,
with a secondary analysis of annual incidence rates; unlike
other multicenter studies involving patients with COPD, the
POET-COPD study focused on the specific and relevant
disease outcome of exacerbations, instead of a wide range
of endpoints. It remains unclear whether the superiority of
tiotropium can be transferred to other LABAs, including the
once-daily LABA indacaterol.14 However, so far, indacaterol
has not been shown to outperform salmeterol or formoterol
in reducing exacerbations from direct comparisons.15,16
In conclusion, our subanalyses of the POET-COPD study
investigated the effect of tiotropium compared with sal-
meterol on time to first exacerbation and the rate of
exacerbations in patients with moderate (GOLD stage II)
COPD and those naı¨ve to maintenance respiratory therapy.
Tiotropium significantly increased time to first exacerba-
tion in both of these patient subgroups, and the annual rate
of exacerbations in the maintenance naı¨ve subgroup
compared to salmeterol. Our results generally support the
primary analyses of the POET-COPD trial, and have
potential implications for clinicians selecting long-acting
bronchodilator therapies, particularly for exacerbation-
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